CRISPR-Cas systems have revolutionized genome editing, and the CRISPR-Cas toolkit has been expanding to include single-base editing enzymes, targeting RNA and fusing inactive Cas proteins to effectors that regulate various nuclear processes. Consequently, CRISPR-Cas systems are being tested for gene and cell therapies.